ArticleInternational journal of women's health2026
Subtype-Specific Causal Effects of Antidiabetic Drug Targets on Ovarian Cancer: Mendelian Randomization and Colocalization Evidence.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ovarian cancer (OC), characterized by a high mortality rate and limited treatment options, underscores the urgent need to identify novel therapeutic targets to advance individualized precision therapy. Exploring the potential of antidiabetic drug target genes as therapeutic candidates may expand the treatment repertoire of diverse OC subtypes. Methods: Leveraging datasets involving the Ovarian Cancer Association Consortium, the eQTLGen consortium, and the Genotype-Tissue Expression database, we implemented an integrated analytical framework combining two-sample Mendelian randomization (MR), summary data-based MR, as well as colocalization analysis to assess the association between target genes of antidiabetic drugs with the risk and survival of different ovarian cancer subtypes. Positive control analysis, replication analysis, MR-Egger regression, Bonferroni correction, and MR-PRESSO outlier test were employed to further validate the robustness of the associations. Results: We systematically analyzed the associations of nine OC phenotypes with the target genes from nine antidiabetic drugs, including sulfonylureas, metformin, alpha-glucosidase inhibitors (AGIs), thiazolidinediones (TZDs), dipeptidyl peptidase 4 inhibitors (DPP4i), glucagon-like peptide-1 analogues (GLP-1A), insulin, sodium-glucose cotransporter 2 inhibitors (SGLT2i) and other drugs. Notably, multiple target genes showed consistent and significant associations with specific OC risk: AKR1A1 with Low grade serous OC; HMGCR and KCNJ11 with clear cell OC; ITGAL and AKR1B1 with mucinous OC; and AKR1A1 and ITGAL with endometrioid OC. Although high grade serous OC risk was linked to certain genes in only one method, its survival was associated with DPP4 in two approaches. Conclusion: This study reveals marked subtype-specific heterogeneity in the genetic relationships between antidiabetic targets and ovarian cancer (OC), pointing to a direction for future translational research into drug repurposing for subtype-specific applications. These findings support a metabolic basis in OC progression and may inform the development of tailored therapeutic strategies based on pathological subtypes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.